A Randomized, Double-Blind, Placebo-Controlled, 4-week Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis
Phase of Trial: Phase II
Latest Information Update: 28 Oct 2013
At a glance
- Drugs IMO 3100 (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Idera Pharmaceuticals
- 28 Oct 2013 Results presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
- 13 May 2013 Results presented at the International Investigative Dermatology meeting, according to an Idera media release.
- 19 Dec 2012 Top-line results published in an Idera Pharmaceuticals media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History